Effects of Mesenchymal Stem Cell-Derived Exosomes on Experimental Autoimmune Uveitis

Lingling Bai1, Hui Shao2, Hongxing Wang3

  • 1Tianjin Medical University Eye Hospital, Eye Institute &School of Optometry and Ophthalmology, Tianjin, 300384, P.R. China.

Scientific Reports
|June 30, 2017
PubMed

Insights

Mesenchymal stem cell-derived exosomes (MSC-Exo) effectively treat experimental autoimmune uveitis (EAU) in rats by reducing inflammatory cell migration to the eyes. This suggests MSC-Exo as a promising therapy for uveitis.

Area of Science:

  • Immunology
  • Ophthalmology
  • Regenerative Medicine

Background:

  • Mesenchymal stem cells (MSCs) show therapeutic potential for experimental autoimmune uveitis (EAU).
  • MSC-derived exosomes (MSC-Exo) are believed to mediate MSC functions.
  • The efficacy of local MSC-Exo administration on established EAU requires investigation.

Purpose of the Study:

  • To evaluate the therapeutic effect of human MSC-Exo on established EAU in rats.
  • To investigate the in vitro mechanisms of MSC-Exo action on immune cells.

Main Methods:

  • Rats with EAU were treated with periocular injections of MSC-Exo.
  • In vitro chemotactic and lymphocyte proliferation assays were performed.
  • Immune cell infiltration in ocular tissues was assessed.

Main Results:

  • MSC-Exo significantly reduced EAU severity and ocular inflammatory cell infiltration.
  • MSC-Exo inhibited the chemoattraction of inflammatory cells mediated by CCL2 and CCL21.
  • MSC-Exo did not inhibit interphotoreceptor retinol-binding protein (IRBP)-specific T cell proliferation.

Conclusions:

  • MSC-Exo ameliorate EAU by suppressing inflammatory cell migration, not T cell proliferation.
  • MSC-Exo represent a potential novel therapeutic strategy for uveitis.